Abstract
Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.
Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.
Current Pharmaceutical Biotechnology
Title:Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Volume: 13 Issue: 10
Author(s): K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee and B. A. Sullenger
Affiliation:
Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.
Abstract: Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.
Export Options
About this article
Cite this article as:
M. Bompiani K., S. Woodruff R., C. Becker R., M. Nimjee S. and A. Sullenger B., Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273137
DOI https://dx.doi.org/10.2174/138920112802273137 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology Descending Necrotizing Mediastinitis: Current Strategies for Diagnosis and Treatment
Current Respiratory Medicine Reviews Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Ambulatory Blood Pressure and Diabetes: Targeting Nondipping
Current Diabetes Reviews Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Genetic Diversity Among Saudi Peganum harmala and Rhazya stricta Populations Using Chemical and ISSR Markers
Current Pharmaceutical Biotechnology Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology An Efficient Synthesis of 7,11-diarylspiro[5.5]undecane-1,9-dione by the Michael Condensation Under Ultrasound Irradiation in Aqueous and Organic Two Phase in the Presence of Phase-Transfer Catalyst
Letters in Organic Chemistry From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Combination of Thiazide Diuretics and Angiotensin Receptor Blockers Attenuates Osteoporosis in Hypertensive Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews